Today's Rundown
| Welcome to Fierce’s daily coronavirus roundup. In order to bring you the most comprehensive and up-to-date information relating to the pandemic, we are publishing additional stories and all of the day’s coronavirus-related news in a PM edition. If you would prefer not to receive this newsletter, you may opt out at any time by clicking here. | |
|
Featured Story | | |
The White House has assembled a COVID-19 task force representing a number of agencies. Here's a look at some of the top healthcare experts on the panel. |
|
|---|
|
Top Stories Monday, March 16, 2020 It’s a pretty extraordinary story that started off with a CEO exiting a biotech and has now become about the U.S. president allegedly wanting to lure that biotech over to the U.S. to build a vaccine for the coronavirus—but just for Americans. Monday, March 16, 2020 A Biogen management meeting held in Boston in late February has spawned 108 confirmed or presumptive positive cases of the novel coronavirus—and now may have led to a criminal investigation. Monday, March 16, 2020
Investors rewarded Moderna for launching its COVID-19 vaccine trial and sent BMS down on worries about next week's ozanimod decision. Closures piled up, President Donald Trump asked young people to avoid big groups, Novartis asked staff to work from home, and South Korea and Israel stocked their virus-fighting medicine chests. Monday, March 16, 2020
FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Friday, March 13, 2020 As the coronavirus is increasingly altering American life, a small survey of physicians finds that some patients are canceling elective procedures because of the outbreak. Financial analysts predict what it means for hospitals and surgery centers. Monday, March 16, 2020 The novel coronavirus is putting pharma's global supply chain under strain, no question. What's up in the air is just how supplies could be affected—and unfortunately, analysts just can't be sure. Why? Lack of transparency, for one thing. For another, it's complicated. Monday, March 16, 2020 Shortly after the FDA granted an Emergency Use Authorization to its first commercially developed coronavirus test—developed by Roche for use on its high-throughput cobas system—the agency did the same for Thermo Fisher Scientific’s diagnostic. Monday, March 16, 2020 At a time of unprecedented panic over the rapidly spreading COVID-19 coronavirus, several research groups are asking whether existing therapies could be repurposed in fighting the disease. Suggestions over the past week include combinations of drugs and supplements as well as a stem cell product that has proven effective in reducing inflammatory biomarkers. Thursday, March 12, 2020 Here are some of the details Providence St. Joseph Health's chief clinical officer Amy Compton Phillips shared about lessons learned treating the first confirmed COVID-19 case in the U.S. during a virtual event hosted by HIMSS. Friday, March 13, 2020 What's the outlook for really fending off the novel coronavirus? Small molecule drugs and other therapeutics will obviously beat vaccines to market, and Gilead's remdesivir, if effective, could scale up fast, experts said. But vaccines are likely further off than quoted timelines suggest. It's 'overly optimistic' to expect them in 12 to 18 months, they told an analyst. Monday, March 16, 2020 Many organizations and companies in the biopharma world have formed alliances to develop drugs and vaccines against the novel coronavirus amid a global pandemic. Now Pfizer, on top its own bilateral team-up, is offering up its resources for wider use. Monday, March 16, 2020 Hospital groups want Congress to suspend the 2% cut to Medicare installed with the sequester to instill a "much-needed jolt" of confidence for hospitals |
|
.jpg/united-states-capitol-1675541_1920%20(1).jpg/741ee4dbccdecfe4873cf2956593f06a)